Johnson & Johnson's Invokana received FDA approval on March 29, 2013.
Invokana is a once-a-day treatment for controlling blood sugar in adults with type 2 diabetes. According to the FDA, it is the first in a new class of diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Invokana blocks the re-absorption of glucose by the kidney, increases glucose excretion, and lowers blood glucose levels in diabetics with elevated blood glucose levels.
Generic name: canagliflozin
FDA announcement: FDA approves Invokana to treat type 2 diabetes
Product website: invokana.com